Comment
doi: 10.3109/14397595.2014.917600.
Epub 2014 Jun 2.
Comments on the paper showing an exceptionally favorable response to tofacitinib among Japanese rheumatoid patients and an issue surrounding clinical trial led by pharmaceutical company
Affiliations
- PMID: 24884482
- DOI: 10.3109/14397595.2014.917600
Item in Clipboard
Comment
Comments on the paper showing an exceptionally favorable response to tofacitinib among Japanese rheumatoid patients and an issue surrounding clinical trial led by pharmaceutical company
Mod Rheumatol.
2015 May.
No abstract available
Keywords: Clinical trial; DMARD; Odds ratio; Tofacitinib.
Comment in
-
Response to Dr Minota's Letter to the Editor of Modern Rheumatology Regarding a Study of Tofacitinib in Japanese Patients with Rheumatoid Arthritis.Mod Rheumatol. 2016;26(2):318-9. doi: 10.3109/14397595.2015.1012799. Mod Rheumatol. 2016. PMID: 25671402 No abstract available.
Comment on
-
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.Arthritis Rheum. 2012 Apr;64(4):970-81. doi: 10.1002/art.33419. Epub 2011 Oct 17. Arthritis Rheum. 2012. PMID: 22006202 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
